T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.48B |
| 2 |
Kenvue
KVUE
|
+$1.5B |
| 3 |
Halliburton
HAL
|
+$1.12B |
| 4 |
Boeing
BA
|
+$950M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$920M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.64B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.66B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.56B |
| 5 |
Amazon
AMZN
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.76% |
| 2 | Healthcare | 16.83% |
| 3 | Financials | 10.91% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
Holley
HLLY
$384M
| $58K | ﹤0.01% |
11,462
+765
| +7% | +$4.33K |
|
|
NXDR
2752
Nextdoor Holdings
NXDR
$986M
| $58K | ﹤0.01% |
31,602
+2,087
| +7% | +$5.17K |
|
|
NAGE
2753
Niagen Bioscience
NAGE
$242M
| $58K | ﹤0.01% |
39,300
| – | – |
|
2754
Ampco-Pittsburgh
AP
$190M
| $57K | ﹤0.01% |
21,600
| – | – |
|
2755
Advantage Solutions
ADV
$399M
| $56K | ﹤0.01% |
782
+152
| +24% | +$10.1K |
|
|
KZR
2756
DELISTED
Kezar Life Sciences
KZR
| $56K | ﹤0.01% |
4,635
+1,870
| +68% | +$33.1K |
|
2757
Rafael Holdings
RFL
$103M
| $56K | ﹤0.01% |
29,731
| – | – |
|
|
TSP
2758
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $56K | ﹤0.01% |
35,566
+3,680
| +12% | +$6.44K |
|
2759
Arbutus Biopharma
ABUS
$908M
| $55K | ﹤0.01% |
26,735
+1,106
| +4% | +$2.32K |
|
|
MMAT
2760
DELISTED
Meta Materials Inc. Common Stock
MMAT
| $54K | ﹤0.01% |
2,546
+1,253
| +97% | +$27.4K |
|
2761
Babcock & Wilcox
BW
$1.46B
| $53K | ﹤0.01% |
12,466
| – | – |
|
2762
Vanda Pharmaceuticals
VNDA
$314M
| $53K | ﹤0.01% |
12,155
+726
| +6% | +$4.03K |
|
2763
Eos Energy Enterprises
EOSE
$1.54B
| $52K | ﹤0.01% |
23,890
+2,058
| +9% | +$6.16K |
|
2764
Inseego
INSG
$82.6M
| $52K | ﹤0.01% |
12,270
| – | – |
|
2765
Ovid Therapeutics
OVID
$489M
| $52K | ﹤0.01% |
13,414
+1,301
| +11% | +$4.68K |
|
2766
Vroom Inc
VRM
$52.1M
| $52K | ﹤0.01% |
570
| – | – |
|
2767
Cardiff Oncology
CRDF
$77.1M
| $51K | ﹤0.01% |
36,500
| – | – |
|
2768
Summit Therapeutics
SMMT
$12B
| $51K | ﹤0.01% |
26,947
+3,435
| +15% | +$6.55K |
|
|
ASXC
2769
DELISTED
Asensus Surgical, Inc.
ASXC
| $51K | ﹤0.01% |
185,500
| – | – |
|
|
ASRT
2770
DELISTED
Assertio
ASRT
| $50K | ﹤0.01% |
1,292
+545
| +73% | +$31.8K |
|
|
FRGE
2771
DELISTED
Forge Global Holdings
FRGE
| $50K | ﹤0.01% |
1,621
+133
| +9% | +$4.87K |
|
2772
Lantronix
LTRX
$275M
| $50K | ﹤0.01% |
11,200
| – | – |
|
2773
Safe Bulkers
SB
$760M
| $50K | ﹤0.01% |
15,375
+1,600
| +12% | +$5.16K |
|
|
TPIC
2774
DELISTED
TPI Composites
TPIC
| $50K | ﹤0.01% |
18,643
-11,400
| -38% | -$69.7K |
|
2775
Nerdy
NRDY
$93.7M
| $49K | ﹤0.01% |
13,146
+2,102
| +19% | +$9.11K |
|
Similar funds
T. Rowe Price Associates's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Associates held 2,959 positions worth $682B, down 4.9% from $718B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.7%. T. Rowe Price Associates opened 69 new positions and exited 71, leaving the 2,959-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2023 buy was Maplebear: 6,435,942 shares worth $191M.
- T. Rowe Price Associates added most to SLB Ltd in Q3 2023, an estimated $2.48B increase.
- T. Rowe Price Associates's biggest Q3 2023 reduction was Microsoft, cutting an estimated $2.64B.
- T. Rowe Price Associates fully exited Life Storage, Inc. in Q3 2023, selling an estimated $285M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $682B portfolio in Q3 2023.
- T. Rowe Price Associates opened 69 new positions and closed 71 in Q3 2023.
- T. Rowe Price Associates's portfolio value fell 4.9% quarter-over-quarter to $682B.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.